Amikacin-containing self-emulsifying delivery systems via pulmonary administration for treatment of bacterial infections of cystic fibrosis patients. (4th May 2018)

• Record Type: Journal Article
• Authors: Hetényi, Gergely; Griesser, Janine; Fontana, Simon; Gutierrez, Anja Martinez; Ellemunter, Helmut; Niedermayr, Katharina; Szabó, Péter; Bernkop-Schnürch, Andreas
• Is Part Of: Nanomedicine. Volume 13:Number 7(2018)
• Page Start: 717
• Page End: 732
• Publication Date: 2018-05-04
• Subjects: amikacin -- CF mucus permeation -- cystic fibrosis -- hydrophobic ion pairing -- self-emulsifying delivery systems -- SEDDS; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm-2017-0307
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: The aim of the study was to develop self-emulsifying delivery systems (SEDDS) exhibiting improved permeation rate for pulmonary delivery of amikacin for treatment of cystic fibrosis (CF) patients.Materials & methods: Solubility of amikacin in lipids was improved by hydrophobic ion pairing with sodium myristyl sulfate. The complex was loaded into SEDDS. Drug-release studies were performed and the permeation properties of SEDDS through human CF mucus were examined.Results: A total of 10% complex could be loaded into SEDDS. SEDDS exhibited sustained release. Up to twofold more amounts of amikacin permeated through the CF mucus compared with reference.Conclusion: The developed SEDDS with amikacin may be a promising tool for the treatment of certain bacterial infections of CF patients.